Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 5, Issue 4
February 23 2021
Issue Cover

Table of Contents

CLINICAL GUIDELINES

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Clinical Trials & Observations
Gary H. Lyman,Marc Carrier,Cihan Ay,Marcello Di Nisio,Lisa K. Hicks,Alok A. Khorana,Andrew D. Leavitt,Agnes Y. Y. Lee,Fergus Macbeth,Rebecca L. Morgan,Simon Noble,Elizabeth A. Sexton,David Stenehjem,Wojtek Wiercioch,Lara A. Kahale,Pablo Alonso-Coello
View Articletitled, American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Supplemental data

STIMULUS REPORTS

Prognostic restaging after treatment initiation in patients with AL amyloidosis
Clinical Trials & Observations
Nadine Abdallah,Angela Dispenzieri,Eli Muchtar,Francis K. Buadi,Prashant Kapoor,Martha Q. Lacy,Yi L. Hwa,Amie Fonder,Miriam A. Hobbs,Suzanne R. Hayman,Nelson Leung,David Dingli,John A. Lust,Ronald S. Go,Yi Lin,Wilson I. Gonsalves,Taxiarchis Kourelis,Rahma Warsame,Robert A. Kyle,S. Vincent Rajkumar,Morie A. Gertz,Shaji K. Kumar
View Articletitled, Prognostic restaging after treatment initiation in patients with AL amyloidosis
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN
Clinical Trials & Observations
Peter M. Voorhees,Cesar Rodriguez,Brandi Reeves,Nitya Nathwani,Luciano J. Costa,Yana Lutska,Padma Bobba,Daniela Hoehn,Huiling Pei,Jon Ukropec,Ming Qi,Thomas S. Lin,Paul G. Richardson
View Articletitled, Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

CLINICAL TRIALS AND OBSERVATIONS

A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial
Clinical Trials & Observations
Ken Ohmachi,Tomohiro Kinoshita,Kensei Tobinai,Gakuto Ogawa,Tomonori Mizutani,Nobuhiko Yamauchi,Noriko Fukuhara,Toshiki Uchida,Kazuhito Yamamoto,Kana Miyazaki,Norifumi Tsukamoto,Shinsuke Iida,Takahiko Utsumi,Isao Yoshida,Yoshitaka Imaizumi,Takashi Tokunaga,Shinichiro Yoshida,Yasufumi Masaki,Tohru Murayama,Yoshihiro Yakushijin,Youko Suehiro,Kisato Nosaka,Nobuaki Dobashi,Junya Kuroda,Yasushi Takamatsu,Dai Maruyama,Kiyoshi Ando,Kenichi Ishizawa,Michinori Ogura,Tadashi Yoshino,Tomomitsu Hotta,Kunihiro Tsukasaki,Hirokazu Nagai,the Japan Clinical Oncology Group
View Articletitled, A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial
Supplemental data
Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression
Clinical Trials & Observations
Richard E. Clark,Jane F. Apperley,Mhairi Copland,Silvia Cicconi
View Articletitled, Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression
Supplemental data
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Clinical Trials & Observations
Bob Löwenberg,Thomas Pabst,Johan Maertens,Patrycja Gradowska,Bart J. Biemond,Olivier Spertini,Edo Vellenga,Laimonas Griskevicius,Lidwine W. Tick,Mojca Jongen-Lavrencic,Marinus van Marwijk Kooy,Marie-Christiane Vekemans,Walter J. F. M. van der Velden,Berna Beverloo,Lucienne Michaux,Carlos Graux,Dries Deeren,Okke de Weerdt,Joost W. J. van Esser,Mario Bargetzi,Saskia K. Klein,Alain Gadisseur,Peter E. Westerweel,Hendrik Veelken,Michael Gregor,Tobias Silzle,Daniëlle van Lammeren-Venema,Ine Moors,Dimitri A. Breems,Mels Hoogendoorn,Marie-Cecile J. C. Legdeur,Thomas Fischer,Juergen Kuball,Jan Cornelissen,Kimmo Porkka,Gunnar Juliusson,Peter Meyer,Martin Höglund,Bjorn T. Gjertsen,Jeroen J. W. M. Janssen,Gerwin Huls,Jakob Passweg,Jacqueline Cloos,Peter J. M. Valk,Catharina H. M. J. van Elssen,Markus G. Manz,Yngvar Floisand,Gert J. Ossenkoppele,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK)
View Articletitled, Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Supplemental data

GENE THERAPY

In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice
Chang Li,Aphrodite Georgakopoulou,Arpit Mishra,Sucheol Gil,R. David Hawkins,Evangelia Yannaki,André Lieber
View Articletitled, In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice
Supplemental data

HEALTH SERVICES AND OUTCOMES

Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia
Kishan K. Patel,Amer M. Zeidan,Rory M. Shallis,Thomas Prebet,Nikolai Podoltsev,Scott F. Huntington
View Articletitled, Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation
Zachary Davis,Martin Felices,Todd Lenvik,Sujan Badal,Joshua T. Walker,Peter Hinderlie,James L. Riley,Daniel A. Vallera,Bruce R. Blazar,Jeffrey S. Miller
View Articletitled, Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation
Supplemental data

LYMPHOID NEOPLASIA

Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion
Bibiana Rius,Jaleh S. Mesgarzadeh,Isabelle C. Romine,Ryan J. Paxman,Jeffery W. Kelly,R. Luke Wiseman
View Articletitled, Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion
Supplemental data

MYELOID NEOPLASIA

Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML
Sylvain Mareschal,Anna Palau,Johan Lindberg,Philippe Ruminy,Christer Nilsson,Sofia Bengtzén,Marie Engvall,Anna Eriksson,Anne Neddermeyer,Vinciane Marchand,Monika Jansson,My Björklund,Fabrice Jardin,Mattias Rantalainen,Andreas Lennartsson,Lucia Cavelier,Henrik Grönberg,Sören Lehmann
View Articletitled, Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML
Supplemental data
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Clinical Trials & Observations
Anthony M. Hunter,Rami S. Komrokji,Seongseok Yun,Najla Al Ali,Onyee Chan,Jinming Song,Mohammad Hussaini,Chetasi Talati,Kendra L. Sweet,Jeffrey E. Lancet,Eric Padron,Alan F. List,David A. Sallman
View Articletitled, Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Supplemental data

PLATELETS AND THROMBOPOIESIS

Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature
Samah Alimam,William Villiers,Richard Dillon,Michael Simpson,Manohursingh Runglall,Alexander Smith,Prodromos Chatzikyriakou,Paul Lavender,Anju Kanda,Ken Mills,Beatriz Bellosillo Paricio,James Kaufman-Cook,Sophie Ord,Shahram Kordasti,Deepti Radia,Claire Woodley,Yvonne Francis,Ghulam Mufti,Donal P. McLornan,Claire N. Harrison
View Articletitled, Patients with triple-negative, <em>JAK2</em>V617F- and <em>CALR</em>-mutated essential thrombocythemia share a unique gene expression signature
Supplemental data

THROMBOSIS AND HEMOSTASIS

Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients
Clinical Trials & Observations
Melissa Yan,Ryan Kieser,Carol C. Wu,Wei Qiao,Cristhiam M. Rojas-Hernandez
View Articletitled, Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients
Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry
Clinical Trials & Observations
Jean-Pierre Bassand,Saverio Virdone,Marc Badoz,Freek W. A. Verheugt,A. John Camm,Frank Cools,Keith A. A. Fox,Samuel Z. Goldhaber,Shinya Goto,Sylvia Haas,Werner Hacke,Gloria Kayani,Frank Misselwitz,Karen S. Pieper,Alexander G. G. Turpie,Martin van Eickels,Ajay K. Kakkar,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators,for the GARFIELD-AF Investigators
View Articletitled, Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry
Supplemental data

TRANSPLANTATION

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors
Michael R. Grunwald,Mei-Jie Zhang,Hany Elmariah,Mariam H. Johnson,Andrew St. Martin,Asad Bashey,Minoo Battiwalla,Christopher N. Bredeson,Edward Copelan,Corey S. Cutler,Biju R. George,Vikas Gupta,Christopher Kanakry,Rohtesh S. Mehta,Filippo Milano,Alberto Mussetti,Ryotaro Nakamura,Taiga Nishihori,Wael Saber,Melhem Solh,Daniel J. Weisdorf,Mary Eapen
View Articletitled, Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

COMMENTARY

Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients
Ghulam Rehman Mohyuddin,Anthony Rooney,Nicole Balmaceda,Muhammad Aziz,Douglas W. Sborov,Brian McClune,Shaji K. Kumar
View Articletitled, Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients
Supplemental data

ERRATUM

Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414-5424.
View Articletitled, Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. <em>Blood Adv.</em> 2020;4(21):5414-5424.
  • Cover Image

    Cover Image

    issue cover

    COVER FIGURE
    Fluorescence in situ hybridization (FISH) analysis in a representative case of pseudomonosomy 7. Whole-chromosome painting (WCP) was done in a case in which conventional karyotyping but not shallow whole genome sequencing (sWGS) reported a monosomy 7. The image shows WCP for chromosome (chr) 7 (green) and chromosome 4 (red) and a probe targeting the centromere of chromosome 7 (blue). Wild-type (WT) chromosomes 4 and 7 can be identified, as well as 2 derivative chromosomes (der) harboring additional chromosome 7 material including 2 chromosome 7 centromeres. sWGS of this case did not show complete loss of a second chromosome 7 but presence of 2 copies or amplification of some parts of the chromosome. See the article by Mareschal et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

Imus PH, Pasca S, Tsai H-L, et al. Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies. Blood Adv. 2024;8(14):3849-3858.
Glisovic-Aplenc T, Diorio C, Chukinas JA, et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 2023;7(16):4418-4430.
Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection
Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals